Viridian Therapeutics, Inc./DE (VRDN) Financial Statements
Viridian Therapeutics, Inc./DE (VRDN) files with the U.S. Securities and Exchange Commission under CIK 0001590750. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- $70.85 million
- Net Income
- -$342.60 million
- Total Assets
- $899.42 million
- Net Cash from Operations
- -$276.39 million
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Aug 6, 2026. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for VRDN in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History